Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor γ activity: A combined virtual screening and biological assay approach

Molecular Pharmacology

Volumn 71, Issue 2, 2007, Pages 398-406

  Scarsi, Marco ^a,b   Podvinec, Michael ^a,b   Roth, Adrian ^a,c   Hug, Hubert ^d,e   Kersten, Sander ^f   Albrecht, Hugo ^g   Schwede, Torsten ^a,b   Meyer, Urs A ^a   Rücker, Christoph ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d TheraSTrat AG   (Switzerland)

^e DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

^f WAGENINGEN UNIVERSITY   (Netherlands)

^g BioFocus DPI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; ANTIDIABETIC AGENT; CARBUTAMIDE; CHLORPROPAMIDE; FARGLITAZAR; GLIBENCLAMIDE; GLIBORNURIDE; GLICARAMIDE; GLICLAZIDE; GLICONDAMIDE; GLIMEPIRIDE; GLINIDE DERIVATIVE; GLIPIZIDE; GLIQUIDONE; GLISAMURIDE; GLISOLAMIDE; GLISOXEPIDE; MEGLITINIDE; METAHEXAMIDE; MITIGLINIDE; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOASSAY; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION; IC 50; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION;

ATP-BINDING CASSETTE TRANSPORTERS; COMPUTER SIMULATION; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; PHENYLALANINE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PPAR GAMMA; PROTEIN BINDING; RECEPTORS, DRUG; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 33846414323     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.024596     Document Type: Article

References (55)

1. Anonymous (2004) Mitiglinide: KAD 1229, S 21403. Drugs R D 5:98-101.
2. Anonymous (2006) Glurenorm, summary of product characteristics (SPC) from the eMC. http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp? DocumentID=6950.
3. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, and Thurlby PL (1994) [[ω-(Heterocyclylamino)alkoxy] benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977-3985.
4. Cox SL (2005) Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barcelona) 41:579-587.
5. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, and Bamberg K (2001) Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706.
6. Culy CR and Jarvis B (2001) Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 61:1625-1660.
7. Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K, van Meeteren LA, Moolenaar WH, Wilke N, Siess W, et al. (2005) Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 48:4919-4930.
8. Ebdrup S, Pettersson I, Rasmussen HB, Deussen HJ, Frost Jensen A, Mortensen SB, Fleckner J, Pridal L, Nygaard L, and Sauerberg P (2003) Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. J Med Chem 46:1306-1317.
9. Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, Heijer M, and Ohman KP (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metab Dispos 32:923-929.
10. Farret A, Lugo-Garcia L, Galtier F, Gross R, and Petit P (2005) Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes. Fundam Clin Pharmacol 19:647-656.
11. Ferry G, Bruneau V, Beauverger P, Goussard M, Rodriguez M, Lamamy V, Dromaint S, Canet E, Galizzi JP, and Boutin JA (2001) Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands. Eur J Pharmacol 417:77-89.
12. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, and Shimomura I (2005) Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 280:23653-23659.
13. Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, and Xu HE (2000) Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5:545-555.
14. Gut J and Bagatto D (2005) Theragenomic knowledge management for individualised safety of drugs, chemicals, pollutants and dietary ingredients. Expert Opin Drug Metab Toxicol 1:537-554.
15. Hatorp V (2002) Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 41:471-483.
16. Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, et al. (2006) Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pract 71:251-255.
17. Hermanson O, Glass CK, and Rosenfeld MG (2002) Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 13:55-60.
18. Hug H, Bagatto D, Dannecker R, Schindler R, Horlacher O, and Gut J (2003) ADRIS-The Adverse Drug Reactions Information Scheme. Pharmacogenetics 13:767-772.
19. Hug H, Dannecker R, Schindler R, Bagatto D, Stephan A, Wess RA, and Gut J (2004) Ontology-based knowledge management of troglitazone-induced hepatotoxicity. Drug Discov Today 9:948-954.
20. Iniguez-Lluhi JA, Lou DY, and Yamamoto KR (1997) Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus. J Biol Chem 272:4149-4156.
21. Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S, Awata T, and Katayama S (2005) Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 328:484-490.
22. Jaber LA, Ducharme MP, Edwards DJ, Slaughter RL, and Grunberger G (1996) The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. Pharmacotherapy 16:760-768.
23. Jönsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JA, and Melander A (2000) Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol 56:711-714.
24. Knouff C and Auwerx J (2004) Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25:899-918.
25. Langtry HD and Balfour JA (1998) Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 55:563-584.
26. Laudet V and Gronemeyer H (2002) The Nuclear Receptor FactBook, Academic Press, London.
27. Luzio SD, Anderson DM, and Owens DR (2001) Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects. J Clin Endocrinol Metab 86:4874-4880.
28. Martin JA, Brooks DA, Prieto L, Gonzalez R, Torrado A, Rojo I, Lopez de Uralde B, Lamas C, Ferritto R, Dolores Martin-Ortega M, et al. (2005) 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. Bioorg Med Chem Lett 15:51-55.
29. McLeod JF (2004) Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 43:97-120.
30. Minoura H, Takeshita S, Ita M, Hirosumi J, Mabuchi M, Kawamura I, Nakajima S, Nakayama O, Kayakiri H, Oku T, et al. (2004) Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol 494:273-281.
31. Momose Y, Maekawa T, Odaka H, Ikeda H, and Sohda T (2002a) Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. Chem Pharm Bull 50:100-111.
32. Momose Y, Maekawa T, Yamano T, Kawada M, Odaka H, Ikeda H, and Sohda T (2002b) Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. J Med Chem 45:1518-1534.
33. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662.
34. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, and Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (Lond) 395:137-143.
35. Owens DR, Luzio SD, Ismail I, and Bayer T (2000) Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 23:518-523.
36. Parker JC (2002) Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Adv Drug Deliv Rev 54:1173-1197.
37. Perfetti R and D'Amico E (2005) Rational drug design and PPAR agonists. Curr Diab Rep 5:340-345.
38. Picard F and Auwerx J (2002) PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167-197.
39. Rangwala SM and Lazar MA (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25:331-336.
40. Renaud JP and Moras D (2000) Structural studies on nuclear receptors. Cell Mol Life Sci 57:1748-1769.
41. Rücker C, Scarsi M, and Meringer M (2006) 2D QSAR of PPARgamma agonist binding and transactivation. Bioorg Med Chem 14:5178-5195.
42. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Woldike HF, Fleckner J, et al. (2002) Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem 45:789-804.
43. Scarsi M, Rücker C, Dannecker R, Hug H, Gut J, and Meyer UA (2005) Molecular modelling of PPARγ agonists. Poster presented at the Third International Symposium on PPARs Efficacy and Safety; March 19-23, 2005; Monte Carlo, Monaco. http://www.lorenzinifoundation.org/ppars2005/abstract_book.pdf, page 39.
44. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, and Freeman BA (2005) Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 102:2340-2345.
45. Shi GQ, Dropinski JF, McKeever BM, Xu S, Becker JW, Berger JP, MacNaul KL, Elbrecht A, Zhou G, Doebber TW, et al. (2005) Design and synthesis of α-aryloxyphenylacetic acid derivatives: a novel class of PPARα/γ dual agonists with potent antihyperglycemic and lipid modulating activity. J Med Chem 48:4457-4468.
46. Staels B and Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54:2460-2470.
47. von Nicolai H, Brickl R, Eschey H, Greischel A, Heinzel G, König E, Limmer J, and Rupprecht E (1997) Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. Arzneimittelforschung 47:247-252.
48. Wang M and Tafuri S (2003) Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 89:38-47.
49. Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, and Mangold JB (2001) Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 29:415-421.
50. World Health Organization (2002) The cost of diabetes. WHO Fact sheet 236. World Health Organization, Geneva, Switzerland. http://www.who.int/hpr/NPH/ docs/gs_diabetes.pdf.
51. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.
52. Willson TM, Lambert MH, and Kliewer SA (2001) Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70:341-367.
53. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403.
54. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, et al. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 98:13919-13924.
55. Yamamoto K, Itoh T, Abe D, Shimizu M, Kanda T, Koyama T, Nishikawa M, Tamai T, Ooizumi H, and Yamada S (2005) Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorg Med Chem Lett 15:517-522.